hotspot -WSS

hotspot

author：fashion 2025-09-27 10:04:27 - browse：655

Two people stare at a keyhole in a human head in between them, as the short-haired person on the left holds a key — first opinion coverage from STAT — Adobe

In many ways, psychiatry is still flying blind. People experiencing mental health conditions are prescribed various drugs until one (or a combination) finally works — a painful process that can take years. As a psychiatrist and neuroscientist, I became increasingly impatient and frustrated with this ineffective way of treating patients. This guided the core question behind my research: Can biology explain how people with the same psychiatric disorder respond differently to the same treatment?

Since I first began exploring this question more than a decade ago, mental illness has become a global epidemic. Despite significant efforts, progress in psychiatric drug development has remained disappointingly slow. There have been a few notable approvals in recent years, and a renewal of interest by Big Pharma, following a retreat from psychiatric research in the mid to late 2000s. But the landscape remains predominantly marked by failures and a dry drug development pipeline. Approved drugs follow the same pattern of prescribing via guesswork, with most patients not responding to a given drug. This cycle of trial-and-error drug development producing trial-and-error treatment arises from a simple source: We have not systematized a process for learning from our failures and successes.

Related: A ‘renaissance in neuroscience’ could deliver a fresh crop of psychiatric medicines

For example, take depression: While the rise of selective serotonin reuptake inhibitors (SSRIs) in the 1980s and 1990s seemed to provide a solution, seminal studies in the 2000s exposed fundamental limitations of our treatment options. Antidepressants are widely prescribed, but their efficacy relative to placebo is modest.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Radiology is caught between AI's potential and concern for patients

hotspot

entertainment

WSS

FDA official pushes for dedicated emerging pathogens team

Artificial intelligence advances fuel industry trying to preserve loved ones after death

Patients' immediate access to test results puts radiologists in a bind

Will.i.am, Britney Spears release new single, 'Mind Your Business'

What causes an itch? Researchers may have solved the mystery

Body of missing toddler recovered in Delaware River days after flood: Police

focus

hotspot

Related: A ‘renaissance in neuroscience’ could deliver a fresh crop of psychiatric medicines

hotspot

Psychedelics group wrestles with new pharma identity

In new study, freeze

Medical leaders decry Supreme Court decision on affirmative action

CDC backtracks, saying fully vaccinated people can go maskless indoors

Bright Health sells Medicare Advantage business to Molina

As Taiwan prepares for anti

How one medical school became remarkably diverse

Pregnancy discrimination could be enabled by AI

New air purifier tech could be key to improving indoor air quality

The woman behind the Dana Farber

Wikipedia

STAT letters to the editor on burnt

Roche to buy Carmot Therapeutics, developer of obesity drugs

Our daughter's deadly disease: trisomy 18. We wanted to protect her

Caitlin Bernard's story shows physicians can't shy from advocacy

FDA needs staff influx to meet gene therapy needs, Marks says

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

focus

entertainment

Wikipedia

focus